Prostate Hypoxia - TIC
关键词
抽象
日期
最后验证: | 07/31/2020 |
首次提交: | 03/11/2014 |
提交的预估入学人数: | 03/19/2014 |
首次发布: | 03/23/2014 |
上次提交的更新: | 08/17/2020 |
最近更新发布: | 08/18/2020 |
实际学习开始日期: | 08/31/2014 |
预计主要完成日期: | 12/31/2027 |
预计完成日期: | 12/31/2027 |
状况或疾病
干预/治疗
Drug: Pimonidazole
相
手臂组
臂 | 干预/治疗 |
---|---|
Other: Pimonidazole | Drug: Pimonidazole Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery. |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | Male |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - Prostate cancer patients with bulky intermediate risk or high-risk disease who have already agreed to undergo an open radical prostatectomy at Princess Margaret Cancer Centre-UHN: - Clinical stage T2-T3 N0 M0 - Pathology of adenocarcinoma of the prostate AND - Gleason score 7 with >/= 50 % biopsies involved with tumour; OR - Gleason score 8 or above (any percentage of biopsies) Exclusion Criteria: - Patients with clinical T4, N1 or M1 disease - Patients with histologies other than adenocarcinoma - Patients unable to ingest pimonidazole tablets |
结果
主要结果指标
1. Quantitation of pimonidazole staining (a.u./cm2) in radical prostatectomy specimens as determinant of biochemical failure [3 years]
次要成果指标
1. Quantitation of tumour initial cells by immunohistochemistry (cells/mm2) in radical prostatectomy specimens as determinant of biochemical failure [3 years]